It Is Possible to Classify Non-erosive Reflux Disease (NERD) Patients into Endoscopically Normal Groups and Minimal Change Groups by Subjective Symptoms and Responsiveness to Rabeprazole—A Report from a Study with Japanese Patients

被引：0

作者：

Motoyasu Kusano

Naohito Shirai

Kanako Yamaguchi

Michio Hongo

Tsutomu Chiba

Yoshikazu Kinoshita

机构：

[1] Gunma University Hospital,Department of Endoscopy and Endoscopic Surgery

[2] Enshu Hospital,Department of Gastroenterology

[3] Saga Medical School,Department of Internal Medicine

[4] Tohoku University Hospital,Departments of Comprehensive Medicine and Psychosomatic Medicine

[5] Kyoto University Graduate School of Medicine,Department of Gastroenterology and Hepatology

[6] Shimane University School of Medicine,Department of Gastroenterology and Hepatology

来源：

Digestive Diseases and Sciences | 2008年 / 53卷

关键词：

NERD; Symptom; Rabeprazole; Minimal change; Questionnaire;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The hypothesis that non-erosive reflux disease (NERD) patients comprise various subgroups is gaining popularity. This study was conducted to investigate the possibility of categorizing NERD patients according to symptom types and response to acid-suppressive drug rabeprazole (RPZ) 10 mg/day. NERD patients were classified as grade N (endoscopically normal), M (minimal change), or erosive GERD, and answered a 51-item, yes-or-no questionnaire pre and post-treatment. Compared to erosive GERD, clear differences existed in pretreatment prevalence of symptoms and responsiveness to RPZ in grades N and M; the results suggested stomachaches (especially at night) were significant symptoms in grade N and dysmotility-like symptoms like bloated stomach were significant in grade M while gastroesophageal reflux symptoms were significant in erosive GERD. Clinical significance of classifying NERD was indicated from different symptoms and responsiveness to PPI.

引用

页码：3082 / 3094

页数：12

共 184 条

[1]

Dent J(1999)An evidence-based appraisal of reflux disease management—the Genval Workshop Report Gut 44 S1-16

[2]

Brun J(2006)The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus Am J Gastroenterol 101 1900-1920

[3]

Fendrick A(1997)Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta analysis Gastroenterology 112 1798-1810

[4]

Fennerty M(2006)Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease Cochrane Database Syst Rev 19 CD002095-S7

[5]

Janssens J(1996)Heartburn: ethnic variations in prevalence and interpretation Gastroenterology 110 A276-763

[6]

Kahrilas P(2003)Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease Am J Gastroenterol 98 S2-773

[7]

Lauritsen K(1997)Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis Aliment Pharmacol Ther 11 755-891

[8]

Reynolds J(1997)Omeprazole 10 milligrams once daily, Omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease-in general practice Scand J Gastroenterol 32 765-54

[9]

Shaw M(2004)Development and evaluation of FSSG; frequency scale for the symptoms of GERD J Gastroenterol 39 888-S23

[10]

Talley N(2006)Symptom diversity of patients with reflux esophagitis: effect of omeprazole treatment J Clin Biochem Nutr 39 46-1464

← 1 2 3 4 5 6 7 8 9 10 →